These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 17954185

  • 1. Long-term maintenance of calcineurin inhibitor monotherapy reduces the risk for squamous cell carcinomas after kidney transplantation compared with bi- or tritherapy.
    Abou Ayache R, Thierry A, Bridoux F, Bauwens M, Belmouaz M, Desport E, Touchard G.
    Transplant Proc; 2007 Oct; 39(8):2592-4. PubMed ID: 17954185
    [Abstract] [Full Text] [Related]

  • 2. Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients.
    Fortina AB, Piaserico S, Caforio AL, Abeni D, Alaibac M, Angelini A, Iliceto S, Peserico A.
    Arch Dermatol; 2004 Sep; 140(9):1079-85. PubMed ID: 15381547
    [Abstract] [Full Text] [Related]

  • 3. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 4. Patients with both basal and squamous cell carcinomas are at a lower risk of further basal cell carcinomas than patients with only a basal cell carcinoma.
    Ramachandran S, Rajaratnam R, Smith AG, Lear JT, Strange RC.
    J Am Acad Dermatol; 2009 Aug; 61(2):247-51. PubMed ID: 19481292
    [Abstract] [Full Text] [Related]

  • 5. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure.
    Carmellini M, Collini A, Ruggieri G, Garosi G, Bernini M.
    Transplant Proc; 2008 Aug; 40(6):1858-61. PubMed ID: 18675070
    [Abstract] [Full Text] [Related]

  • 6. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience.
    Gheith OA, Bakr MA, Fouda MA, Shokeir AA, Bayoumy A, Sobh M, Ghoneim M.
    Iran J Kidney Dis; 2008 Jan; 2(1):34-9. PubMed ID: 19367007
    [Abstract] [Full Text] [Related]

  • 7. Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression.
    Kandaswamy R, Humar A, Casingal V, Gillingham KJ, Ibrahim H, Matas AJ.
    Transplantation; 2007 Mar 27; 83(6):722-6. PubMed ID: 17414704
    [Abstract] [Full Text] [Related]

  • 8. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R, Cinti P, Lai Q, Poli L, Berloco PB.
    Transpl Immunol; 2008 Nov 27; 20(1-2):3-5. PubMed ID: 18773959
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 11. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
    Nashan B.
    Transplant Rev (Orlando); 2009 Jan 27; 23(1):47-52. PubMed ID: 19027616
    [Abstract] [Full Text] [Related]

  • 12. Increased incidence of acute graft rejection on calcineurin inhibitor-free immunosuppression after heart transplantation.
    Celik S, Doesch AO, Konstandin MH, Kristen AV, Ammon K, Sack FU, Schnabel P, Katus HA, Dengler TJ.
    Transplant Proc; 2011 Jun 27; 43(5):1862-7. PubMed ID: 21693290
    [Abstract] [Full Text] [Related]

  • 13. Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors.
    Wisgerhof HC, Edelbroek JR, de Fijter JW, Haasnoot GW, Claas FH, Willemze R, Bavinck JN.
    Transplantation; 2010 May 27; 89(10):1231-8. PubMed ID: 20410852
    [Abstract] [Full Text] [Related]

  • 14. Development of lymphoproliferative disease after liver transplantation.
    Marqués E, Jiménez C, Manrique A, Vallejo GH, Clemares M, Ortega P, Moreno E.
    Transplant Proc; 2008 Nov 27; 40(9):2988-9. PubMed ID: 19010169
    [Abstract] [Full Text] [Related]

  • 15. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F.
    Liver Transpl; 2009 Oct 27; 15(10):1262-9. PubMed ID: 19790150
    [Abstract] [Full Text] [Related]

  • 16. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 17. Alemtuzumab and minimization immunotherapy in kidney transplantation: long-term results of comparison with rabbit anti-thymocyte globulin and standard triple maintenance therapy.
    Zachariah M, Nader ND, Brar J, Singh N, Venuto R, Patel S, Said M, Laftavi MR, Pankewycz O.
    Transplant Proc; 2014 Nov 15; 46(1):94-100. PubMed ID: 24507032
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
    Kahan BD.
    Transplant Proc; 2008 Dec 15; 40(10 Suppl):S17-20. PubMed ID: 19100899
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.